Contraception for antiphospholipid syndrome and systemic lupus erythematosus (according to the recommendations of the European Alliance of Associations for Rheumatology/American College of Rheumatology, EULAR/ACR)
https://doi.org/10.47360/1995-4484-2024-13-23
Abstract
Maintaining and strengthening the health of the population is one of the primary functions of society. Inadequate understanding of the importance of contraception by the medical community and its application by society can lead to the population’s reproductive health becoming compromised. Basic knowledge of effective and safe contraceptive methods is important for every rheumatologist, as reproductive health affects both the general condition of patients and the course of the main rheumatic diseases (RH). This is particularly true for patients with antiphospholipid antibody (aPL) positivity, antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE). The presence of aPL/APS, as well as the activity of SLE, are the main factors determining the choice of contraceptive method and the risk of hormonal contraception in patients with RH. Meanwhile, the use of appropriate (highly effective and safe) contraceptive therapy in this category of patients allows not only to plan the birth of a child, but also to avoid unwanted pregnancy in cases of disease activity, the use of embryotoxic and teratogenic drugs, as well as to carry out optimal treatment of concomitant pathology, which the supervising rheumatologist should be well aware of. This publication is devoted to the consideration of the main issues of contraception in the most “vulnerable” category of patients with RH – with positive aPL, APS and SLE.
About the Authors
T. M. Reshetnyak
V.A. Nasonova Research Institute of Rheumatology;
Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Tatiana M. Reshetnyak
115522, Moscow, Kashirskoye Highway, 34A;
125993, Moscow, Barrikadnaya str., 2/1, building 1
S. B. Kertchelaeva
N.I. Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Svetlana B. Kertchelaeva
117997, Moscow, Ostrovitianova str., 1
N. M. Kosheleva
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Nadezhda M. Kosheleva
115522, Moscow, Kashirskoye Highway, 34A
References
1. Oboskalova TA (ed.). Methods of contraception and criteria for their use. Textbook. Ekaterinburg;2019 (In Russ.)
2. National medical criteria for the acceptability of contraceptive methods. Adapted document “Medical eligibility criteria for the use of WHO contraceptive methods, 5th edition, 2015”. Moscow;2023 (In Russ.)
3. Sukhikh GT, Prilepskaya VN, Aganezova NV, Andreeva EN, Baranov II, Dolgushina NV, et al. Contraception in women of reproductive age. Textbook. Moscow:Binom;2019 (In Russ.)
4. Sumiatina LV. Modern hormonal contraceptives: new options. Russian Journal of Human Reproduction. 2014;(6):46-48 (In Russ.)
5. Trussell J. Contraceptive failure in the United States. Contraception. 2011;83(5):397-404. doi: 10.1016/j.contraception.2011.01.021
6. Kestelman P, Trussell J. Efficacy of the simultaneous use of condoms and spermicides. Fam Plan Perspect. 1991;23(5):226-227,232.
7. Nazarova NM, Prilepskaya VN. Estrogen-progestogen releasing systems: A new look at contraception (literature review). Pharmateka. 2009;(14):10-16 (In Russ.)
8. Williams WV. Hormonal contraception and the development of autoimmunity: A review of the literature. Linacre Q. 2017;84(3): 275-295. doi: 10.1080/00243639.2017.1360065
9. Iwata M, Oikawa Y, Shimizu Y, Sakashita N, Shoji A, Igarashi A, et al. Efficacy of low-dose estrogen-progestins and progestins in Japanese women with dysmenorrhea: A systematic review and network meta-analysis. Adv Ther. 2022;39(11):4892-4909. doi: 10.1007/s12325-022-02298-9
10. Prilepskaya VN. Novaring – contraception, anatomy, sexology. Gynecology. 2004;6(6):306-308 (In Russ.)
11. Prilepskaya VN, Nazarova NM. New technologies in contraception: Hormonal releasing systems. Gynecology. 2005;7(1):41-44 (In Russ.)
12. Khialani D, Rosendaal F, Vlieg AVH. Hormonal contraceptives and the risk of venous thrombosis. Semin Thromb Hemost. 2020;46(8):865-871. doi: 10.1055/s-0040-1715793
13. Medical Eligibility Criteria for Contraceptive Use. 5th ed. Geneva: World Health Organization; 2015. https://ww.who.int/reproductivehealth/publications/family_planning/Ex-Summ-MEC-5/en/
14. Amy JJ, Tripathi V. Contraception for women: An evidence-based overview. BMJ. 2009;339:b2895. doi: 10.1136/bmj.b2895
15. Winner B, Peipert JF, Zhao Q, Buckel C, Madden T, Allsworth JE, et al. Effectiveness of long-acting reversible contraception. N Engl J Med. 2012;366(21):1998-2007. doi: 10.1056/NEJMoa1110855
16. Kavanaugh ML, Pliskin E. Use of contraception among reproductive-aged women in the United States, 2014 and 2016. F S Rep. 2020;1(2):83-93. doi: 10.1016/j.xfre.2020.06.006
17. Sammaritano LR, Bermas BL, Chakravarty EE, Chambers C, Clowse MEB, Lockshin MD, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Care Res (Hoboken). 2020;72(4):461-488. doi: 10.1002/acr.24130
18. Nasonov EL (ed.). Antiphospholipid syndrome. Moscow:Litterra;2004 (In Russ.)
19. Reshetnyak TM. Antiphospholipid syndrome: Diagnosis and clinical manifestations (a lecture). NauchnoPrakticheskaya Revmatologia = Rheumatology Science and Practice. 2014;52(1):56-71 (In Russ.) doi: 10.14412/1995-4484-2014-56-71
20. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306. doi: 10.1111/j.1538-7836.2006.01753.x
21. Schwarz EB, Manzi S. Risk of unintended pregnancy among women with systemic lupus erythematosus. Arthritis Rheum. 2008;59(6):863-866. doi: 10.1002/art.23712
22. Yazdany J, Trupin L, Kaiser R, Schmajuk G, Gillis JZ, Chakravarty E, et al. Contraceptive counseling and use among women with systemic lupus erythematosus: A gap in health care quality? Arthritis Care Res (Hoboken). 2011;63(3):358-365. doi: 10.1002/acr.20402
23. Brunson MR, Klein DA, Olsen CH, Weir LF, Roberts TA. Postpartum contraception: Initiation and effectiveness in a large universal healthcare system. Am J Obstet Gynecol. 2017;217(1): 55.e1-55.e9. doi: 10.1016/j.ajog.2017.02.036
24. Mendel A, Bernatsky S, Pineau CA, St-Pierre Y, Hanly JG, Urowitz MB, et al. Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. Rheumatology (Oxford). 2019;58(7):1259-1267. doi: 10.1093/rheumatology/kez014
25. DeNoble AE, Hall KS, Xu X, Zochowski MK, Piehl K, Dalton VK. Receipt of prescription contraception by commercially insured women with chronic medical conditions. Obstet Gynecol. 2014;123(6):1213-1220. doi: 10.1097/AOG.0000000000000279
26. Champaloux SW, Tepper NK, Curtis KM, Zapata LB, Whiteman MK, Marchbanks PA, et al. Contraceptive use among women with medical conditions in a nationwide privately insured population. Obstet Gynecol. 2015;126(6):1151-1159. doi: 10.1097/AOG.0000000000001134
27. Birru Talabi M, Clowse MEB, Blalock SJ, Moreland L, Siripong N, Borrero S. Contraception use among reproductive-age women with rheumatic diseases. Arthritis Care Res (Hoboken). 2019;71(8):1132-1140. doi: 10.1002/acr.23724
28. Danowski A, de Azevedo MN, de Souza Papi JA, Petri M. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol. 2009;36(6):1195-1199. doi: 10.3899/jrheum.081194
29. Erkan D, Harrison MJ, Levy R, Peterson M, Petri M, Sammaritano L, et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: A randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum. 2007;56(7):2382-2391. doi: 10.1002/art.22663
30. Brouwer JL, Bijl M, Veeger NJ, Kluin-Nelemans HC, van der Meer J. The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus. Blood. 2004;104(1):143-148. doi: 10.1182/blood-2003-11-4085
31. Girolami A, Zanon E, Zanardi S, Saracino MA, Simioni P. Thromboembolic disease developing during oral contraceptive therapy in young females with antiphospholipid antibodies. Blood Coagul Fibrinolysis. 1996;7(4):497-501. doi: 10.1097/00001721-199606000-00011
32. Bacci S, Urquiola G, del Médico P, Sanabria JA, Bacci JC, Guzmán M, et al. Síndrome de Budd-Chiari, tromboembolismo pulmonar y trombosis venosa profunda, asociado con “anticoagulante lúpico” y uso reciente de anticonceptivos orales [Budd-Chiari syndrome, pulmonary thromboembolism, and deep venous thrombosis associated with “lupus anticoagulant” and recent use of oral contraceptives]. G E N. 1990;44(3):237-242 (In Spanish).
33. Urbanus RT, Siegerink B, Roest M, Rosendaal FR, de Groot PG, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: A case-control study. Lancet Neurol. 2009;8(11):998-1005. doi: 10.1016/S1474-4422(09)70239-X
34. Sammaritano LR.Which hormones and contraception for women with APS? Exogenous hormone use in women with APS. Curr Rheumatol Rep. 2021;23(6):44. doi: 10.1007/s11926-021-01006-w
35. Iskander MK, Khan M. Chorea as the initial presentation of oral contraceptive related systemic lupus erythematosus. J Rheumatol. 1989;16(6):850-851.
36. Yamakami LY, de Araujo DB, Silva CA, Baracat EC, de Carvalho JF. Severe hemorrhagic corpus luteum complicating anticoagulation in antiphospholipid syndrome. Lupus. 2011;20(5):523-526. doi: 10.1177/0961203310383300
37. Crétel E, Cacoub P, Huong DL, Gompel A, Amoura Z, Piette JC. Massive ovarian haemorrhage complicating oral anticoagulation in the antiphospholipid syndrome: A report of three cases. Lupus. 1999;8(6):482-485. doi: 10.1177/096120339900800614
38. ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol. 2006;107(6):1453-1472. doi: 10.1097/00006250-200606000-00055
39. Pisoni CN, Cuadrado MJ, Khamashta MA, Hunt BJ. Treatment of menorrhagia associated with oral anticoagulation: Efficacy and safety of the levonorgestrel releasing intrauterine device (Mirena coil). Lupus. 2006;15(12):877-880. doi: 10.1177/0961203306071706
40. Rebelo RC, Pignaton E, Valeria Bahamondes M, Costallat LTL, Appenzeller S, Bahamondes L, et al. Disease activity and thromboembolic events in women with systemic lupus erythematosus with and without anti-phospholipid syndrome: Users of the 52-mg levonorgestrel-releasing intrauterine system. Arch Gynecol Obstet. 2019;299(6):1597-1605. doi: 10.1007/s00404-019-05131-x
41. van Vlijmen EF, Veeger NJ, Middeldorp S, Hamulyák K, Prins MH, Büller HR, et al. Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: A rational approach to contraception. Blood. 2011;118(8):2055-2061;quiz 2375. doi: 10.1182/blood-2011-03-345678
42. Klok FA, Barco S. Optimal management of hormonal contraceptives after an episode of venous thromboembolism. Thromb Res. 2019;181(Suppl 1):1-5. doi: 10.1016/S0049-3848(19)30357-3
43. Martinelli I, Lensing AW, Middeldorp S, Levi M, Beyer-Westendorf J, van Bellen B, et al. Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. Blood. 2016;127(11):1417-1425. doi: 10.1182/blood2015-08-665927
44. Panevin TS, Popkova TV, Reshetnyak TM, Kosheleva NM, Ledina AV. Menopausal hormone therapy for systemic lupus erythematosus: Pro et contra. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2023;61(1):70-76 (In Russ.) doi: 10.47360/1995-4484-2023-70-76
45. The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24(7):728-753. doi: 10.1097/GME.0000000000000921
46. U.S. Preventive Services Task Force. Hormone therapy for the prevention of chronic conditions in postmenopausal women: Recommendations from the U.S. Preventive Services Task Force. Ann Intern Med. 2005;142(10):855-860.
47. Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362(9382):419-427. doi: 10.1016/s0140-6736(03)14065-2
48. Менопауза и климактерическое состояние у женщин: Клинические рекомендации МЗ РФ. М.;2021. [Menopause and climacteric condition in women. Clinical recommendations of the Ministry of Health of the Russian Federation. Moscow;2021 (In Russ.)].
49. Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, et al.; Women’s Health Initiative Investigators. Estrogen plus progestin and risk of venous thrombosis. JAMA. 2004;292(13):1573-1580. doi: 10.1001/jama.292.13.1573
50. Marjoribanks J, Farquhar C, Roberts H, Lethaby A. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2012;(7):CD004143. doi: 10.1002/14651858
51. Smith NL, Heckbert SR, Lemaitre RN, Reiner AP, Lumley T, Weiss NS, et al. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA. 2004;292(13):1581-1587. doi: 10.1001/jama.292.13.1581
52. Sweetland S, Beral V, Balkwill A, Liu B, Benson VS, Canonico M, et al.; Million Women Study Collaborators. Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. J Thromb Haemost. 2012;10(11):2277-2286. doi: 10.1111/j.1538-7836.2012.04919.x
53. Straczek C, Oger E, Yon de Jonage-Canonico MB, Plu-Bureau G, Conard J, Meyer G, et al.; Estrogen and Thromboembolism Risk (ESTHER) Study Group. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: Impact of the route of estrogen administration. Circulation. 2005; 112(22):3495-3500. doi: 10.1161/CIRCULATIONAHA.105.565556
54. Rosendaal FR, Vessey M, Rumley A, Daly E, Woodward M, Helmerhorst FM, et al. Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br J Haematol. 2002;116(4):851-854. doi: 10.1046/j.0007-1048.2002.03356.x
55. Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Lévesque H, et al.; Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: Impact of the route of estrogen administration and progestogens: The ESTHER study. Circulation. 2007;115(7):840-845. doi: 10.1161/CIRCULATIONAHA.106.642280
56. Rovinski D, Ramos RB, Fighera TM, Casanova GK, Spritzer PM. Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: A systematic review and meta-analysis. Thromb Res. 2018;168:83-95. doi: 10.1016/j.thromres.2018.06.014
57. Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: Systematic review and meta-analysis. BMJ. 2008;336(7655):1227-1231. doi: 10.1136/bmj.39555.441944.BE
58. Pinkerton JV, James AH. Management of menopausal symptoms for women who are at high risk of thrombosis. Clin Obstet Gynecol. 2018;61(2):260-268. doi: 10.1097/GRF.0000000000000358
59. Krause MS, Nakajima ST. Hormonal and nonhormonal treatment of vasomotor symptoms. Obstet Gynecol Clin North Am. 2015;42(1):163-179. doi: 10.1016/j.ogc.2014.09.008
60. Nelson HD, Vesco KK, Haney E, Fu R, Nedrow A, Miller J, et al. Nonhormonal therapies for menopausal hot flashes: Systematic review and meta-analysis. JAMA. 2006;295(17):2057-2071. doi: 10.1001/jama.295.17.2057
61. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013;20(9):888-902;quiz 903-904. doi: 10.1097/GME.0b013e3182a122c2
62. Bhupathiraju SN, Grodstein F, Stampfer MJ, Willett WC, Crandall CJ, Shifren JL, et al. Vaginal estrogen use and chronic disease risk in the Nurses’ Health Study. Menopause. 2018;26(6):603-610. doi: 10.1097/GME.0000000000001284
63. de Melo AS, Dos Reis RM, Ferriani RA, Vieira CS. Hormonal contraception in women with polycystic ovary syndrome: Choices, challenges, and noncontraceptive benefits. Open Access J Contracept. 2017;8:13-23. doi: 10.2147/OAJC.S85543
64. Vercellini P, Buggio L, Frattaruolo MP, Borghi A, Dridi D, Somigliana E. Medical treatment of endometriosis-related pain. Best Pract Res Clin Obstet Gynaecol. 2018;51:68-91. doi: 10.1016/j.bpobgyn.2018.01.015
65. Yuk JS, Song JY, Lee JH, Park WI, Ahn HS, Kim HJ. Levonorgestrel-releasing intrauterine systems versus oral cyclic medroxyprogesterone acetate in endometrial hyperplasia therapy: A meta-analysis. Ann Surg Oncol. 2017;24(5):1322-1329. doi: 10.1245/s10434-016-5699-9
66. Grandone E, Di Micco PP, Villani M, Colaizzo D, FernándezCapitán C, Del Toro J, et al.; RIETE Investigators. Venous thromboembolism in women undergoing assisted reproductive technologies: Data from the RIETE registry. Thromb Haemost. 2018;118(11):1962-1968. doi: 10.1055/s-0038-1673402
67. Machin N, Ragni MV. Hormones and thrombosis: Risk across the reproductive years and beyond. Transl Res. 2020;225:9-19. doi: 10.1016/j.trsl.2020.06.011
68. Xu X, Chlebowski RT, Shi J, Barac A, Haque R. Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors. Breast Cancer Res Treat. 2019;174(3):785-794. doi: 10.1007/s10549-018-05086-8
69. Getahun D, Nash R, Flanders WD, Baird TC, Becerra-Culqui TA, Cromwell L, et al. Cross-sex hormones and acute cardiovascular events in transgender persons: A cohort study. Ann Intern Med. 2018;169(4):205-213. doi: 10.7326/M17-2785
70. Goldstein Z, Khan M, Reisman T, Safer JD. Managing the risk of venous thromboembolism in transgender adults undergoing hormone therapy. J Blood Med. 2019;10:209-216. doi: 10.2147/JBM.S166780
71. Duan B, Zhang Y, Wang X, Zhang Y, Hou Y, Bai J, et al. Effect of megestrol acetate combined with oral nutrition supplement in malnourished lung cancer patients: A single-center prospective cohort study. Front Nutr. 2021;8:654194. doi: 10.3389/fnut.2021.654194
72. Poulter NR, Chang CL, Farley TM, Meirik O. Risk of cardiovascular diseases associated with oral progestagen preparations with therapeutic indications. Lancet. 1999;354(9190):1610. doi: 10.1016/s0140-6736(99)03132-3
73. Аномальные маточные кровотечения. Клинические рекомендации МЗ РФ. М.;2021. [Abnormal uterine bleeding. Clinical recommendations of the Ministry of Health of the Russian Federation. Moscow;2021 (In Russ.)].
Review
For citations:
Reshetnyak T.M., Kertchelaeva S.B., Kosheleva N.M. Contraception for antiphospholipid syndrome and systemic lupus erythematosus (according to the recommendations of the European Alliance of Associations for Rheumatology/American College of Rheumatology, EULAR/ACR). Rheumatology Science and Practice. 2024;62(1):13-23. (In Russ.) https://doi.org/10.47360/1995-4484-2024-13-23
Views:
1245
Email this article 